CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Alcon spin-off approved by Novartis shareholders

Alcon will operate as a standalone company following completion of the spin-off in the second quarter of 2019

Business people shake hands

Novartis shareholders have approved the proposed spin-off of its Alcon eye care division, following endorsement from the Novartis board of directors.

The spin-off is expected to be completed in the second quarter of 2019 and will see Alcon operate as a standalone company. However, its completion is subject to conditions, such as the receipt of necessary authorisations.

The change will be implemented through the distribution of a dividend-in-kind of new Alcon shares to Novartis shareholders and American Depositary Receipt holders. 

General manager at Alcon UK and Ireland, Chantelle Cook, said: “If the spin-off takes place, Alcon will be the world’s leading global eye care device company. We expect the spin-off will take place in the second quarter of 2019, possibly as early as April.”

Image credit: Getty